CLINTON, N.J., Jan. 8 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that its President & CEO, Daniel Tasse, will present at the 27th Annual JPMorgan Healthcare Conference on Wednesday, January 14, 2009 at 8:00 a.m., PST. The conference will be held January 12-15 at The Westin St. Francis Hotel in San Francisco.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns(1), and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.
(1) INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.
For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.
Samina Bari Ikaria (908) 238-6372 email@example.com Jason Rando/Jen Saunders The Ruth Group (646) 536-7025/7011 firstname.lastname@example.org email@example.com
|SOURCE Ikaria Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved